A melanoma arising from the choroid, ciliary body, or the iris. It is characterized by the presence of a mixture of spindle A melanoma cells, spindle B melanoma cells, and epithelioid melanoma cells.
Comprehensive, easy-to-understand information about this condition
How we create this content →Documentation on mixed cell uveal melanoma is limited due to its rarity, as conditions affecting fewer than 10,000 people often lack extensive clinical studies. The absence of identified genes and established inheritance patterns further complicates the understanding of this disease. As research continues, the hope is that more information will become available to better characterize the clinical features and management of this condition.
To navigate your care for mixed cell uveal melanoma, consider seeking a specialist in ocular oncology or a medical oncologist with experience in melanoma treatment. You can find valuable resources through the National Organization for Rare Disorders (NORD) at rarediseases.org, which offers information and support for rare diseases. Additionally, inquire about any available patient registries or natural history studies that may provide insights into your condition and potential treatment options.
Currently, there is one FDA-approved orphan drug for mixed cell uveal melanoma: tebentafusp-tebn. Additionally, several other drugs are designated for development, including various novel compounds targeting different pathways. Unfortunately, there are no clinical trials available at this time. For updates on ongoing research, you can search for related studies at ClinicalTrials.gov.
Actionable guidance for navigating care for mixed cell uveal melanoma
To navigate your care for mixed cell uveal melanoma, consider seeking a specialist in ocular oncology or a medical oncologist with experience in melanoma treatment. You can find valuable resources through the National Organization for Rare Disorders (NORD) at rarediseases.org, which offers information and support for rare diseases. Additionally, inquire about any available patient registries or natural history studies that may provide insights into your condition and potential treatment options.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Documentation on mixed cell uveal melanoma is limited due to its rarity, as conditions affecting fewer than 10,000 people often lack extensive clinical studies. The absence of identified genes and established inheritance patterns further complicates the understanding of this disease. As research continues, the hope is that more information will become available to better characterize the clinical features and management of this condition.
To navigate your care for mixed cell uveal melanoma, consider seeking a specialist in ocular oncology or a medical oncologist with experience in melanoma treatment. You can find valuable resources through the National Organization for Rare Disorders (NORD) at rarediseases.org, which offers information and support for rare diseases. Additionally, inquire about any available patient registries or natural history studies that may provide insights into your condition and potential treatment options.
Currently, there is one FDA-approved orphan drug for mixed cell uveal melanoma: tebentafusp-tebn. Additionally, several other drugs are designated for development, including various novel compounds targeting different pathways. Unfortunately, there are no clinical trials available at this time. For updates on ongoing research, you can search for related studies at ClinicalTrials.gov.
Actionable guidance for navigating care for mixed cell uveal melanoma
To navigate your care for mixed cell uveal melanoma, consider seeking a specialist in ocular oncology or a medical oncologist with experience in melanoma treatment. You can find valuable resources through the National Organization for Rare Disorders (NORD) at rarediseases.org, which offers information and support for rare diseases. Additionally, inquire about any available patient registries or natural history studies that may provide insights into your condition and potential treatment options.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Documentation on mixed cell uveal melanoma is limited due to its rarity, as conditions affecting fewer than 10,000 people often lack extensive clinical studies. The absence of identified genes and established inheritance patterns further complicates the understanding of this disease. As research continues, the hope is that more information will become available to better characterize the clinical features and management of this condition.
To navigate your care for mixed cell uveal melanoma, consider seeking a specialist in ocular oncology or a medical oncologist with experience in melanoma treatment. You can find valuable resources through the National Organization for Rare Disorders (NORD) at rarediseases.org, which offers information and support for rare diseases. Additionally, inquire about any available patient registries or natural history studies that may provide insights into your condition and potential treatment options.
Currently, there is one FDA-approved orphan drug for mixed cell uveal melanoma: tebentafusp-tebn. Additionally, several other drugs are designated for development, including various novel compounds targeting different pathways. Unfortunately, there are no clinical trials available at this time. For updates on ongoing research, you can search for related studies at ClinicalTrials.gov.
Actionable guidance for navigating care for mixed cell uveal melanoma
To navigate your care for mixed cell uveal melanoma, consider seeking a specialist in ocular oncology or a medical oncologist with experience in melanoma treatment. You can find valuable resources through the National Organization for Rare Disorders (NORD) at rarediseases.org, which offers information and support for rare diseases. Additionally, inquire about any available patient registries or natural history studies that may provide insights into your condition and potential treatment options.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Consider asking your healthcare providers these condition-specific questions
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.